RecruitingPhase 1NCT06056921

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing Precision Biotech Co., Ltd
Principal Investigator
Liyun Zhang, M.D
Shanxi Bethune Hospital
Intervention
CD19 targeted CAR-T cells(biological)
Enrollment
24 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06056921 on ClinicalTrials.gov

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

← Back to all trials